Oct.10. 2022 eXCELL, Inc., granted a pre-pre-Investigational IND for Regulatory Advice on CBER products INTERACT meeting with U.S. FDA
eXCELL, Inc., a leader in developing the next generation of xenogeneic cell immunotherapies for canc...
10
10 月